<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03045861</url>
  </required_header>
  <id_info>
    <org_study_id>200911</org_study_id>
    <nct_id>NCT03045861</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults</brief_title>
  <official_title>A Phase 2a, Multicenter, Randomized, Adaptive, Open-label, Dose Ranging Study to Evaluate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Cobicistat-boosted GSK2838232 Monotherapy Over 10 Days in HIV-1 Infected Treatment-naive Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK2838232 is a novel HIV-1 maturation inhibitor (MI) that is being developed for the
      treatment of HIV-1 infection in combination with other antiretroviral therapy (ART). This
      study will be a 10-day monotherapy, open-label, adaptive, dose ranging, repeat-dose study.
      This study will be conducted in two Parts (Part A and Part B) consisting single daily doses
      of GSK2838232 and Cobicistat from Day 1 to Day 10. This proof of concept open-label study
      will be aimed to characterize the acute antiviral activity, pharmacokinetics (PK), the
      relationship between PK and antiviral activity, and safety of GSK2838232/cobi administered
      across a range of doses over 10 days in HIV-1 infected patients. A cohort of 10 subjects will
      be studied in Part I followed by interim (go/no-go) analysis of Part A data. On completion of
      an interim analysis of part A data, further cohorts of 8 subjects will then be studied in
      Part B in a parallel design in two or more cohorts (depending upon the data obtained in Part
      A). Approximately 34 HIV-1 infected treatment-naive subjects will be enrolled during the
      study. Subjects in both parts will have a screening visit within 30 days prior to first dose
      and a follow-up visit 7-14 days after the last dose. Maximum duration of study participation
      will be approximately 6 Weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2017</start_date>
  <completion_date type="Actual">April 23, 2018</completion_date>
  <primary_completion_date type="Actual">April 23, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Decline From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA)</measure>
    <time_frame>Baseline (Day 1) to Day 21</time_frame>
    <description>Plasma samples were collected for quantitative analysis of plasma HIV-1 RNA. An HIV-1 RNA polymerase chain reaction (PCR) assay with a lower limit of detection (LLOD) of 50 copies/milliliter (ultrasensitive assay) was used for post-baseline assessments. Baseline value was the value at latest pre-dose assessment. The maximum decline was determined using change from Baseline in plasma HIV-RNA values at each time point. The analysis was performed on Intent To Treat (ITT) Population which comprised of all participants who met study criteria and were enrolled into the study with documented evidence of having received at least 1 dose of treatment and at least one post-Baseline HIV-1 RNA measurement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; other important medical events; is associated with liver injury and impaired liver function. Safety Population comprised of all participants who received at least one dose of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinical Chemistry Abnormalities of Potential Clinical Importance</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>Blood samples were collected for the assessment of clinical chemistry parameters. The clinical concern range for the parameters were: carbon dioxide/bicarbonate (low: &lt;18 millimoles per liter [mmol/L] and high: &gt;32 mmol/L); urea (high: &gt;9 mmol/L); creatinine (high: change from Baseline &gt;44.2 micromoles per liter [µmol/L]), glucose (low: &lt;3 and high: &gt;9 mmol/L); potassium (low: &lt;3 and high: &gt;5.5 mmol/L); troponin I (high: &gt;=0.01 micrograms per liter [µg/L]) and sodium (low: &lt;130 mmol/L and high: &gt;150 mmol/L). Data for any visit post-Baseline is reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Hematology Parameter Abnormalities of Potential Clinical Importance</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameters. The clinical concern range for the parameters were: hematocrit (high: &gt;0.54 proportion of red blood cells in blood); hemoglobin (high: &gt;180 grams per liter [g/L]), lymphocytes (low: &lt;0.8x10^9 cells/L); neutrophil count (low: &lt;1.5x10^9 cells/L); platelet count (low: &lt;100x10^9 cells/L and high: &gt;550x10^9 cells/L); white blood cells (low: &lt;3x10^9 cells/L and high: &gt;20x10^9cells/L). Data for any visit post-Baseline is reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Liver Function Laboratory Abnormalities of Potential Clinical Importance</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>Blood samples were collected for the assessment of liver function parameters. The clinical concern range for liver function parameters were: albumin (low: &lt;30 g/L), total protein (low: &lt;15 and high: &gt;15 g/L), alanine aminotransferase (high: &gt;=2 times upper limit of normal [ULN]); aspartate aminotransferase (high: &gt;=2 times ULN); alkaline phosphatase (high: &gt;=2 times ULN); total bilirubin (high: &gt;=1.5 times ULN); direct bilirubin (high: &gt;0.3 times ULN).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Urine Parameters</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>Urine samples were collected for the assessment of following urine parameters by dipstick method: pH, glucose, protein, blood and ketones. The number of participants with abnormal urine parameters is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram (ECG) Findings</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>Triplicate 12-lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and corrected QT (QTc) intervals. Number of participants with abnormal ECG findings at worst-case post Baseline is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Signs Data Outside Clinical Concern Range</measure>
    <time_frame>Day 1 (pre-dose)</time_frame>
    <description>Vital signs were measured in a semi-supine position after 5 minutes rest and included temperature, systolic and diastolic blood pressure and pulse rate. The clinical concern range for vital signs were: systolic blood pressure (SBP) (low: &lt;85 and high: &gt;160 millimeters of mercury [mmHg]) and diastolic blood pressure (DBP) (low: &lt;45 and high: &gt;100 mmHg). Number of participants with vital signs data outside clinical concern range is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Were Administered Concomitant Medications</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>Concomitant medications (prescription and non-prescription) were administered only as medically necessary during the study. Number of participants who received any concomitant medications is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Zero (Pre-dose) to 24 Hours (AUC[0 to 24]) for GSK2838232 on Day 1</measure>
    <time_frame>Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 1</time_frame>
    <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232. The analysis was performed on Pharmacokinetic Population which comprised of participants who received GSK2838232 and underwent plasma pharmacokinetic sampling during the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for GSK2838232 on Day 1</measure>
    <time_frame>Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 1</time_frame>
    <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Concentration (Tmax) for GSK2838232 on Day 1</measure>
    <time_frame>Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 1</time_frame>
    <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absorption Lag Time (Tlag) for GSK2838232 on Day 1</measure>
    <time_frame>Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 1</time_frame>
    <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of GSK2838232 at 24 Hours Post-dose on Day 1</measure>
    <time_frame>24 hours post-dose on Day 1</time_frame>
    <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve Over the Dosing Interval (AUC [0 to Tau]) for GSK2838232 on Day 10</measure>
    <time_frame>Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 10</time_frame>
    <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre-dose Concentration (C0) of GSK2838232 on Day 10</measure>
    <time_frame>Pre dose on Day 10</time_frame>
    <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration at End of Dosing Interval (Ctau) for GSK2838232 on Day 10</measure>
    <time_frame>24 hours post-dose on Day 10</time_frame>
    <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for GSK2838232 on Day 10</measure>
    <time_frame>Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 10</time_frame>
    <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance of GSK2838232 Following Administration on Day 10</measure>
    <time_frame>Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 10</time_frame>
    <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-life (T1/2) of GSK2838232 Following Administration on Day 10</measure>
    <time_frame>Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 10</time_frame>
    <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for GSK2838232 Following Administration on Day 10</measure>
    <time_frame>Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 10</time_frame>
    <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 11 in log10 Plasma HIV-1 RNA Relative to Day 10 AUC (0 to Tau)</measure>
    <time_frame>Baseline (Day 1), Days 10 and 11</time_frame>
    <description>Plasma samples were collected for quantitative analysis of HIV-1 RNA. Change from Baseline is the value at indicated time point minus Baseline value. Statistical analysis for relationship between pharmacokinetic parameters (AUC) and pharmacodynamic measures (Change from Baseline in plasma HIV-1 RNA) was explored using a frequentist three parameter Emax non-linear model. The model parameters estimated included: maximum response (Emax), pharmacokinetic parameter value that attains 50% of the maximal effect (ED50) and residual variability (s2e). Pharmacokinetic/Pharmacodynamic Population comprised of participants who met criteria for Per-Protocol (all participants who met study criteria and are enrolled into the study with documented evidence of having received all doses and all post-baseline HIV-1 RNA measurement, with exceptions of those who have at least one major protocol deviation) and Pharmacokinetic Population analysis sets and who underwent pharmacodynamic sampling during study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 11 in log10 Plasma HIV-1 RNA Relative to Day 10 Cmax</measure>
    <time_frame>Baseline (Day 1), Days 10 and 11</time_frame>
    <description>Plasma samples were collected for quantitative analysis of HIV-1 RNA. Change from Baseline is the value at indicated time point minus Baseline value. Statistical analysis for the relationship between pharmacokinetic parameters (Cmax) and pharmacodynamic measures (change from Baseline in log10 plasma HIV-1 RNA) was explored using a frequentist three parameter Emax non-linear model. The model parameters estimated included: maximum response (Emax), pharmacokinetic parameter value that attains the 50% of the maximal effect (ED50) and s2e.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 11 in log10 Plasma HIV-1 RNA Relative to Day 10 Ctau</measure>
    <time_frame>Baseline (Day 1), Days 10 and 11</time_frame>
    <description>Plasma samples were collected for quantitative analysis of HIV-1 RNA. Change from Baseline is the value at indicated time point minus Baseline value. Statistical analysis for the relationship between pharmacokinetic parameters (Ctau) and pharmacodynamic measures (change from Baseline in log10 plasma HIV-1 RNA) was explored using a frequentist three parameter Emax non-linear model. The model parameters estimated included: maximum response (Emax), pharmacokinetic parameter value that attains the 50% of the maximal effect (ED50) and s2e.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Count to Day 11</measure>
    <time_frame>Baseline (Day 1) and Day 11</time_frame>
    <description>CD4+ cell counts were assessed by flow cytometry. Baseline value is the latest pre-dose assessment value. Change from Baseline is calculated as the post-dose visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 11 in CD4+ Count Relative to Day 10 AUC (0 to Tau)</measure>
    <time_frame>Baseline (Day 1), Days 10 and 11</time_frame>
    <description>The relationship between pharmacokinetic parameters (AUC) and pharmacodynamic measures (change from Baseline CD4+ cell count) was explored using a frequentist linear model. The model parameters estimated included slope and intercept. The estimate (slope) along with 95% confidence interval is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 11 in CD4+ Count Relative to Day 10 Cmax</measure>
    <time_frame>Baseline (Day 1), Days 10 and 11</time_frame>
    <description>The relationship between pharmacokinetic parameters (Cmax) and pharmacodynamic measures (change from Baseline CD4+ cell count) was explored using a frequentist linear model. The model parameters estimated included slope and intercept. The estimate (slope) along with 95% confidence interval is presented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 11 in CD4+ Count Relative to Day 10 Ctau</measure>
    <time_frame>Baseline (Day 1), Days 10 and 11</time_frame>
    <description>The relationship between pharmacokinetic parameters (Ctau) and pharmacodynamic measures (change from Baseline CD4+ cell count) was explored using a frequentist linear model. The model parameters estimated included slope and intercept. The estimate (slope) along with 95% confidence interval is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Emergent Drug Resistance Mutations</measure>
    <time_frame>Up to Day 11</time_frame>
    <description>Plasma samples were collected to evaluate treatment-emergent genotypic mutations in Gag, reverse transcriptase (RT) and protease (PR) and to assess phenotypic resistance to GSK2838232 and RT and PR drugs. Number of participants with treatment emergent RT/PR mutations, reduced susceptibility to nucleoside/nucleotide reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), or protease inhibitor (PI), treatment emergent maturation inhibitor A364A/V and GSK2838232 phenotypic resistance is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio for GSK2838232</measure>
    <time_frame>pre dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Days 1 and 10; pre-dose on Days 3, 4, 5, 8 and 9; Days 12 and 14</time_frame>
    <description>Serial blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232. The accumulation ratios were calculated as R_AUC=AUC(0-tau) Day 10/AUC(0-24) Day 1; R_Cmax=Cmax Day 10/Cmax Day 1 and R_Ctau=Ctau Day 10/C24 Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Proportionality of GSK2838232</measure>
    <time_frame>pre dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Days 1 and 10</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232. Dose proportionality was assessed using a fixed effects power model. Estimated slope and 90% confidence interval is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-morning Dose Concentrations (C0) on Day 2 Through 11</measure>
    <time_frame>Pre-dose on Days 2, 3, 4, 5, 8, 9, 10 and 11</time_frame>
    <description>Blood samples were collected for pharmacokinetic analysis of GSK2838232. The pre-morning dose concentrations for Days 2 to 11 is presented. One participant from GSK2838232 100 mg arm was dosed with GSK2838232 50 mg on Days 1 and 2; hence, pharmacokinetic parameters for that participant were summarized with GSK2838232 50 mg for Days 1 and 2 and with GSK2838232 100 mg for Days 3 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady State Assessment of Plasma Pre-dose Concentrations by Treatment</measure>
    <time_frame>Pre-dose on Days 8, 9 and 10</time_frame>
    <description>A linear mixed model using Day, treatment and Day by treatment as fixed effects and participant as a random effect on the log-transformed pre-dose values was performed to evaluate if steady state was achieved using the Helmert transformation approach. The comparison was done as Day 8 versus the average of Days 9 and 10 values. The ratio of geometric least square mean for Day 8 versus average of Days 9 and 10 values is presented along with 95% confidence interval.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Cohort 1-GSK2838232 100 mg + Cobicistat 150 mg in Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During Part A (Cohort 1), subjects will receive a single dose of GSK2838232 100 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2-GSK2838232 200 mg + Cobicistat 150 mg in Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During Part B (Cohort 2), subjects will receive a single dose of GSK2838232 200 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3-GSK2838232 50 mg + Cobicistat 150 mg in Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During Part B (Cohort 3), subjects will receive a single dose of GSK2838232 50 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4-GSK2838232 20 mg + Cobicistat 150 mg in Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During Part B (Cohort 4), subjects will receive a single dose of GSK2838232 20 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2838232</intervention_name>
    <description>GSK2838232 capsules will be supplied as swedish orange, unmarked capsule (50 mg), and white, unmarked capsules (10 mg) in high-density polyethylene bottles.</description>
    <arm_group_label>Cohort 1-GSK2838232 100 mg + Cobicistat 150 mg in Part A</arm_group_label>
    <arm_group_label>Cohort 2-GSK2838232 200 mg + Cobicistat 150 mg in Part B</arm_group_label>
    <arm_group_label>Cohort 3-GSK2838232 50 mg + Cobicistat 150 mg in Part B</arm_group_label>
    <arm_group_label>Cohort 4-GSK2838232 20 mg + Cobicistat 150 mg in Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobicistat</intervention_name>
    <description>Cobicistat tablets 150 mg will be supplied as an orange, round, biconvex, film-coated tablet in bulk containers for individualized dosing.</description>
    <arm_group_label>Cohort 1-GSK2838232 100 mg + Cobicistat 150 mg in Part A</arm_group_label>
    <arm_group_label>Cohort 2-GSK2838232 200 mg + Cobicistat 150 mg in Part B</arm_group_label>
    <arm_group_label>Cohort 3-GSK2838232 50 mg + Cobicistat 150 mg in Part B</arm_group_label>
    <arm_group_label>Cohort 4-GSK2838232 20 mg + Cobicistat 150 mg in Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 55 years of age inclusive, at the time of signing the informed consent.

          -  Healthy (other than HIV infection) male or female as determined by the investigator or
             medically qualified designee based on a medical evaluation including medical history,
             physical examination, laboratory tests and cardiac monitoring, defined as no other
             chronic medical conditions and taking no chronic medications.

          -  A subject with a clinical abnormality or laboratory parameter(s) which is/are not
             specifically listed in the inclusion or exclusion criteria, outside the reference
             range for the population being studied may be included only if the investigator in
             consultation with the medical monitor agree and document that the finding is unlikely
             to introduce additional risk factors and will not interfere with the study procedures.

          -  A creatinine clearance &gt;80 mL/minute as determined by Cockcroft-Gault equation
             creatinine clearance CLcr (mL/minute) = (140 - age) x weight (Wt) divided by (72 x
             serum creatinine [Scr]) (times 0.85 if female) where age is in years, Wt is in
             kilogram (kg), and Scr is in units of mg/decilitre (dL).

          -  Confirmed HIV positive; CD4+ cell count &gt;=350 cells/millimetre (mm)^3 and plasma HIV-1
             RNA &gt;=5000 copies/mL at screening.

          -  No current and no prior ART.

          -  Body weight &gt;=50 kg (110 pound [lbs.]) for men and &gt;=45 kg (99 lbs) for women and body
             mass index (BMI) within the range 18.5-31.0 kg/meter^2 (inclusive)

          -  A female subject of reproductive or non-reproductive potential is eligible to
             participate if she is not pregnant (as confirmed by a negative serum or urine human
             chorionic gonadotrophin (hCG) test at screening and prior to first dose), not
             lactating, and at least one of the following conditions applies: females of
             reproductive potential may only be enrolled if they are using two forms of
             complementary contraception, which must include one barrier method. They will be
             counselled on safer sex practices; there is no definitive drug-drug interaction (DDI)
             information with GSK2838232 and an interaction with oral contraceptives is possible,
             so other (barrier, inter-uterine device etc.) methods of contraception will be
             required; fertile females, who have an established, long-term lifestyle of sexual
             abstinence, or only same sex partners, require no other means of birth control.
             Pre-menopausal females with one of the following: documented tubal ligation;
             documented hysteroscopic tubal occlusion procedure with follow-up confirmation of
             bilateral tubal occlusion; hysterectomy; documented bilateral oophorectomy;
             postmenopausal defined as 12 months of spontaneous amenorrhea in questionable cases a
             blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels
             consistent with menopause. Females on hormone replacement therapy (HRT) must
             discontinue HRT to allow confirmation of post-menopausal status prior to study
             enrolment.

          -  Male subjects with female partners of child bearing potential must comply with the
             following contraception requirements from the time of first dose of study medication
             until one week after the last dose of study medication; vasectomy with documentation
             of azoospermia; male condom plus partner use of one of the contraceptive options as:
             Contraceptive sub dermal implant including a &lt;1 percent rate of failure per year;
             intrauterine device or intrauterine system including a &lt;1 percent rate of failure per
             year; oral contraceptive, either combined or progestogen alone or injectable
             progestogen; contraceptive vaginal ring; percutaneous contraceptive patches. These
             allowed methods of contraception are only effective when used consistently, correctly
             and in accordance with the product label. The investigator is responsible for ensuring
             that subjects understand how to properly use these methods of contraception.

          -  Capable of giving signed informed consent.

        Exclusion Criteria:

          -  Alanine aminotransferase (ALT) and bilirubin (BIL) &gt;1.5 x upper limit of normal (ULN),
             isolated BIL &gt;1.5xULN is acceptable if BIL is fractionated and direct BIL &lt;35 percent.

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones); hepatitis B
             virus (HBV) and/or hepatitis C virus (HCV) positive.

          -  Subjects who have any other chronic medical condition, including cardiovascular (CV),
             respiratory, neurologic, psychiatric, renal, gastrointestinal (GI), oncologic,
             rheumatologic, or dermatologic.

          -  Medical history of cardiac arrhythmias or cardiac disease or a family or personal
             history of long QT syndrome.

          -  Unable to refrain from the use of prescription or non-prescription drugs, including
             vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or
             14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is
             longer) prior to the first dose of study medication, unless in the opinion of the
             Investigator and GSK medical monitor the medication will not interfere with the study
             procedures or compromise subject safety.

          -  History of regular alcohol consumption within 6 months of the study defined as: an
             average weekly intake of &gt;14 drinks for males or &gt;7 drinks for females. One drink is
             equivalent to 12 grams (g) of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL)
             of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.

          -  Smoking is an exclusion criteria for this study. Subject having urinary cotinine
             levels indicative of smoking at screening.

          -  Chronic marijuana or use of other elicit medications (cocaine, heroin) is an exclusion
             criteria.

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the investigator or medical
             monitor, contraindicates their participation.

          -  Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test
             result at screening or within 3 months prior to first dose of study treatment.

          -  Screening or Baseline cardiac troponin I greater than the 99 percent cutoff (&gt;0.045
             nanogram [ng]/mL by the Dimension Vista cardiac troponin [CTN] I assay).

          -  A positive pre-study drug/alcohol screen.

          -  Prior history of receiving an HIV maturation inhibitor

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within 56 days.

          -  The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day.

          -  Treatment with radiation therapy or cytotoxic chemotherapeutic agents within 30 days
             of study drug administration or anticipated need for such treatment within the study.

          -  Treatment with immunomodulating agents (such as systemic corticosteroids,
             interleukins, interferons) or any agent with known anti-HIV activity (such as
             hydroxyurea or foscarnet) within 30 days of study drug administration.

          -  An active Center for Disease Control and Prevention (CDC) category C disease except
             cutaneous Kaposi's sarcoma not requiring systemic therapy during the trial.

          -  Treatment with any vaccine within 30 days prior to receiving study medication.

          -  Exclusion criteria for 24-hour screening holter: any symptomatic arrhythmia (except
             isolated extra systoles); sustained cardiac arrhythmias (such as atrial fibrillation,
             flutter or supraventricular tachycardia [&gt;=10 seconds]); non-sustained or sustained
             ventricular tachycardia (defined as &gt;=3 consecutive ventricular ectopic beats); any
             conduction abnormality including but not specific to left or complete bundle branch
             block, atrioventricular (AV) block, high grade or complete heart block
             Wolff-Parkinson-White (WPW) syndrome etc.; sinus pauses &gt;3 seconds.

          -  Exclusion criteria for screening ECG (a single repeat is allowed for eligibility
             determination): heart rate &lt;45 and &gt;100 beats per minute (bpm) for males, and &lt;50 and
             &gt;100 bpm for females; PR Interval &lt;120 and &gt;220 milliseconds (msec); QRS duration &lt;70
             and &gt;120 msec; corrected QT (QTc) interval &gt;450 msec; Evidence of previous myocardial
             infarction (Does not include ST segment changes associated with repolarization); any
             conduction abnormality (including but not specific to left or right complete bundle
             branch block, AV block [2nd degree or higher], WPW syndrome); sinus pauses &gt;3 seconds;
             any significant arrhythmia which, in the opinion of the principal investigator or GSK
             medical monitor, will interfere with the safety for the individual subject;
             non-sustained or sustained ventricular tachycardia (&gt;=3 consecutive ventricular
             ectopic beats).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <zip>48072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>DeJesus E, Harward S, Jewell RC, Johnson M, Dumont E, Wilches V, Halliday F, Talarico CL, Jeffrey J, Gan J, Xu J, Felizarta F, Scribner A, Ramgopal M, Benson P, Johns BA. A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection. Clin Infect Dis. 2019 Nov 26. pii: ciz938. doi: 10.1093/cid/ciz938. [Epub ahead of print]</citation>
    <PMID>31769793</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 12, 2017</study_first_submitted>
  <study_first_submitted_qc>February 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2017</study_first_posted>
  <results_first_submitted>April 1, 2019</results_first_submitted>
  <results_first_submitted_qc>May 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 29, 2019</results_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cobicistat</mesh_term>
    <mesh_term>GSK2838232</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD is available via the Clinical Study Data Request site (click on the link provided below)</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>https://clinicalstudydatarequest.com/Posting.aspx?ID=20281</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03045861/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03045861/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a dose ranging study to evaluate the antiviral effect, safety, tolerability and pharmacokinetics of cobicistat-boosted GSK2838232 monotherapy over 10 days in human immunodeficiency virus-1 (HIV-1) infected participants.</recruitment_details>
      <pre_assignment_details>A total of 85 participants were screened across 21 sites in the United States and Canada of which 52 participants failed screening. Thirty three participants were enrolled from 15 sites in the United States and Canada.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK2838232 20 mg</title>
          <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
        </group>
        <group group_id="P2">
          <title>GSK2838232 50 mg</title>
          <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
        </group>
        <group group_id="P3">
          <title>GSK2838232 100 mg</title>
          <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
        </group>
        <group group_id="P4">
          <title>GSK2838232 200 mg</title>
          <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A (Up to 10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B (Up to 10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK2838232 20 mg</title>
          <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
        </group>
        <group group_id="B2">
          <title>GSK2838232 50 mg</title>
          <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
        </group>
        <group group_id="B3">
          <title>GSK2838232 100 mg</title>
          <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
        </group>
        <group group_id="B4">
          <title>GSK2838232 200 mg</title>
          <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.4" spread="5.59"/>
                    <measurement group_id="B2" value="25.4" spread="9.74"/>
                    <measurement group_id="B3" value="31.8" spread="10.66"/>
                    <measurement group_id="B4" value="35.8" spread="14.87"/>
                    <measurement group_id="B5" value="29.8" spread="11.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race, customized</title>
              <category_list>
                <category>
                  <title>American Indian or Alaska native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian-South East Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White-White/Caucasian/European Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple-Black or African American and White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Decline From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA)</title>
        <description>Plasma samples were collected for quantitative analysis of plasma HIV-1 RNA. An HIV-1 RNA polymerase chain reaction (PCR) assay with a lower limit of detection (LLOD) of 50 copies/milliliter (ultrasensitive assay) was used for post-baseline assessments. Baseline value was the value at latest pre-dose assessment. The maximum decline was determined using change from Baseline in plasma HIV-RNA values at each time point. The analysis was performed on Intent To Treat (ITT) Population which comprised of all participants who met study criteria and were enrolled into the study with documented evidence of having received at least 1 dose of treatment and at least one post-Baseline HIV-1 RNA measurement.</description>
        <time_frame>Baseline (Day 1) to Day 21</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Decline From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA)</title>
          <description>Plasma samples were collected for quantitative analysis of plasma HIV-1 RNA. An HIV-1 RNA polymerase chain reaction (PCR) assay with a lower limit of detection (LLOD) of 50 copies/milliliter (ultrasensitive assay) was used for post-baseline assessments. Baseline value was the value at latest pre-dose assessment. The maximum decline was determined using change from Baseline in plasma HIV-RNA values at each time point. The analysis was performed on Intent To Treat (ITT) Population which comprised of all participants who met study criteria and were enrolled into the study with documented evidence of having received at least 1 dose of treatment and at least one post-Baseline HIV-1 RNA measurement.</description>
          <population>ITT Population</population>
          <units>Copies per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42095.14" spread="37575.520"/>
                    <measurement group_id="O2" value="-49065.88" spread="71339.743"/>
                    <measurement group_id="O3" value="-32947.50" spread="54291.492"/>
                    <measurement group_id="O4" value="-33149.13" spread="31785.663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; other important medical events; is associated with liver injury and impaired liver function. Safety Population comprised of all participants who received at least one dose of study treatment.</description>
        <time_frame>Up to Day 22</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; other important medical events; is associated with liver injury and impaired liver function. Safety Population comprised of all participants who received at least one dose of study treatment.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Chemistry Abnormalities of Potential Clinical Importance</title>
        <description>Blood samples were collected for the assessment of clinical chemistry parameters. The clinical concern range for the parameters were: carbon dioxide/bicarbonate (low: &lt;18 millimoles per liter [mmol/L] and high: &gt;32 mmol/L); urea (high: &gt;9 mmol/L); creatinine (high: change from Baseline &gt;44.2 micromoles per liter [µmol/L]), glucose (low: &lt;3 and high: &gt;9 mmol/L); potassium (low: &lt;3 and high: &gt;5.5 mmol/L); troponin I (high: &gt;=0.01 micrograms per liter [µg/L]) and sodium (low: &lt;130 mmol/L and high: &gt;150 mmol/L). Data for any visit post-Baseline is reported.</description>
        <time_frame>Up to Day 22</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Chemistry Abnormalities of Potential Clinical Importance</title>
          <description>Blood samples were collected for the assessment of clinical chemistry parameters. The clinical concern range for the parameters were: carbon dioxide/bicarbonate (low: &lt;18 millimoles per liter [mmol/L] and high: &gt;32 mmol/L); urea (high: &gt;9 mmol/L); creatinine (high: change from Baseline &gt;44.2 micromoles per liter [µmol/L]), glucose (low: &lt;3 and high: &gt;9 mmol/L); potassium (low: &lt;3 and high: &gt;5.5 mmol/L); troponin I (high: &gt;=0.01 micrograms per liter [µg/L]) and sodium (low: &lt;130 mmol/L and high: &gt;150 mmol/L). Data for any visit post-Baseline is reported.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Carbon dioxide/bicarbonate; &gt;32 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carbon dioxide/bicarbonate; &lt;18 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea; &gt;9 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Change &gt;44.2 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; &gt;9 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; &lt;3 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; &gt;5.5 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; &lt;3 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; &gt;150 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; &lt;130 mmol/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Troponin I; &gt;=0.01 µg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Hematology Parameter Abnormalities of Potential Clinical Importance</title>
        <description>Blood samples were collected for the assessment of hematology parameters. The clinical concern range for the parameters were: hematocrit (high: &gt;0.54 proportion of red blood cells in blood); hemoglobin (high: &gt;180 grams per liter [g/L]), lymphocytes (low: &lt;0.8x10^9 cells/L); neutrophil count (low: &lt;1.5x10^9 cells/L); platelet count (low: &lt;100x10^9 cells/L and high: &gt;550x10^9 cells/L); white blood cells (low: &lt;3x10^9 cells/L and high: &gt;20x10^9cells/L). Data for any visit post-Baseline is reported.</description>
        <time_frame>Up to Day 22</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hematology Parameter Abnormalities of Potential Clinical Importance</title>
          <description>Blood samples were collected for the assessment of hematology parameters. The clinical concern range for the parameters were: hematocrit (high: &gt;0.54 proportion of red blood cells in blood); hemoglobin (high: &gt;180 grams per liter [g/L]), lymphocytes (low: &lt;0.8x10^9 cells/L); neutrophil count (low: &lt;1.5x10^9 cells/L); platelet count (low: &lt;100x10^9 cells/L and high: &gt;550x10^9 cells/L); white blood cells (low: &lt;3x10^9 cells/L and high: &gt;20x10^9cells/L). Data for any visit post-Baseline is reported.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit; &gt;0.54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; decline from Baseline &gt;0.075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; &gt;180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; decline from Baseline &gt;25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; &lt;0.8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; &lt;1.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; &gt;550</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; &lt;100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cells; &gt;20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cells; &lt;3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Liver Function Laboratory Abnormalities of Potential Clinical Importance</title>
        <description>Blood samples were collected for the assessment of liver function parameters. The clinical concern range for liver function parameters were: albumin (low: &lt;30 g/L), total protein (low: &lt;15 and high: &gt;15 g/L), alanine aminotransferase (high: &gt;=2 times upper limit of normal [ULN]); aspartate aminotransferase (high: &gt;=2 times ULN); alkaline phosphatase (high: &gt;=2 times ULN); total bilirubin (high: &gt;=1.5 times ULN); direct bilirubin (high: &gt;0.3 times ULN).</description>
        <time_frame>Up to Day 22</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Liver Function Laboratory Abnormalities of Potential Clinical Importance</title>
          <description>Blood samples were collected for the assessment of liver function parameters. The clinical concern range for liver function parameters were: albumin (low: &lt;30 g/L), total protein (low: &lt;15 and high: &gt;15 g/L), alanine aminotransferase (high: &gt;=2 times upper limit of normal [ULN]); aspartate aminotransferase (high: &gt;=2 times ULN); alkaline phosphatase (high: &gt;=2 times ULN); total bilirubin (high: &gt;=1.5 times ULN); direct bilirubin (high: &gt;0.3 times ULN).</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin; &lt;30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein; ULN+15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein; lower limit of normal (LLN)-15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; &gt;=2 times ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; &gt;=2 times ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; &gt;=2 times ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin; &gt;=1.5 times ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin; &gt;=0.3 times ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Urine Parameters</title>
        <description>Urine samples were collected for the assessment of following urine parameters by dipstick method: pH, glucose, protein, blood and ketones. The number of participants with abnormal urine parameters is presented.</description>
        <time_frame>Up to Day 22</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Urine Parameters</title>
          <description>Urine samples were collected for the assessment of following urine parameters by dipstick method: pH, glucose, protein, blood and ketones. The number of participants with abnormal urine parameters is presented.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Electrocardiogram (ECG) Findings</title>
        <description>Triplicate 12-lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and corrected QT (QTc) intervals. Number of participants with abnormal ECG findings at worst-case post Baseline is presented.</description>
        <time_frame>Up to Day 22</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Electrocardiogram (ECG) Findings</title>
          <description>Triplicate 12-lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and corrected QT (QTc) intervals. Number of participants with abnormal ECG findings at worst-case post Baseline is presented.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal-not clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal-clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Signs Data Outside Clinical Concern Range</title>
        <description>Vital signs were measured in a semi-supine position after 5 minutes rest and included temperature, systolic and diastolic blood pressure and pulse rate. The clinical concern range for vital signs were: systolic blood pressure (SBP) (low: &lt;85 and high: &gt;160 millimeters of mercury [mmHg]) and diastolic blood pressure (DBP) (low: &lt;45 and high: &gt;100 mmHg). Number of participants with vital signs data outside clinical concern range is presented.</description>
        <time_frame>Day 1 (pre-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs Data Outside Clinical Concern Range</title>
          <description>Vital signs were measured in a semi-supine position after 5 minutes rest and included temperature, systolic and diastolic blood pressure and pulse rate. The clinical concern range for vital signs were: systolic blood pressure (SBP) (low: &lt;85 and high: &gt;160 millimeters of mercury [mmHg]) and diastolic blood pressure (DBP) (low: &lt;45 and high: &gt;100 mmHg). Number of participants with vital signs data outside clinical concern range is presented.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP; &gt;Clinical concern range</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; &lt;Clinical concern range</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; &gt;Clinical concern range</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; &lt;Clinical concern range</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Were Administered Concomitant Medications</title>
        <description>Concomitant medications (prescription and non-prescription) were administered only as medically necessary during the study. Number of participants who received any concomitant medications is presented.</description>
        <time_frame>Up to Day 22</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Administered Concomitant Medications</title>
          <description>Concomitant medications (prescription and non-prescription) were administered only as medically necessary during the study. Number of participants who received any concomitant medications is presented.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Time Curve From Zero (Pre-dose) to 24 Hours (AUC[0 to 24]) for GSK2838232 on Day 1</title>
        <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232. The analysis was performed on Pharmacokinetic Population which comprised of participants who received GSK2838232 and underwent plasma pharmacokinetic sampling during the study.</description>
        <time_frame>Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 1</time_frame>
        <population>Pharmacokinetic Population. One participant from GSK2838232 100 mg arm was dosed with GSK2838232 50 mg on Days 1 and 2; hence, pharmacokinetic parameters for that participant were summarized with GSK2838232 50 mg for Day 1</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Time Curve From Zero (Pre-dose) to 24 Hours (AUC[0 to 24]) for GSK2838232 on Day 1</title>
          <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232. The analysis was performed on Pharmacokinetic Population which comprised of participants who received GSK2838232 and underwent plasma pharmacokinetic sampling during the study.</description>
          <population>Pharmacokinetic Population. One participant from GSK2838232 100 mg arm was dosed with GSK2838232 50 mg on Days 1 and 2; hence, pharmacokinetic parameters for that participant were summarized with GSK2838232 50 mg for Day 1</population>
          <units>Hours*nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187" spread="35.5"/>
                    <measurement group_id="O2" value="453" spread="60.4"/>
                    <measurement group_id="O3" value="966" spread="67.4"/>
                    <measurement group_id="O4" value="2752" spread="51.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentration (Cmax) for GSK2838232 on Day 1</title>
        <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
        <time_frame>Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 1</time_frame>
        <population>Pharmacokinetic Population. One participant from GSK2838232 100 mg arm was dosed with GSK2838232 50 mg on Days 1 and 2; hence, pharmacokinetic parameters for that participant were summarized with GSK2838232 50 mg for Day 1</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) for GSK2838232 on Day 1</title>
          <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
          <population>Pharmacokinetic Population. One participant from GSK2838232 100 mg arm was dosed with GSK2838232 50 mg on Days 1 and 2; hence, pharmacokinetic parameters for that participant were summarized with GSK2838232 50 mg for Day 1</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.65" spread="36.4"/>
                    <measurement group_id="O2" value="32.39" spread="61.0"/>
                    <measurement group_id="O3" value="65.62" spread="76.7"/>
                    <measurement group_id="O4" value="190.0" spread="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Observed Concentration (Tmax) for GSK2838232 on Day 1</title>
        <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
        <time_frame>Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 1</time_frame>
        <population>Pharmacokinetic Population. One participant from GSK2838232 100 mg arm was dosed with GSK2838232 50 mg on Days 1 and 2; hence, pharmacokinetic parameters for that participant were summarized with GSK2838232 50 mg for Day 1</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Concentration (Tmax) for GSK2838232 on Day 1</title>
          <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
          <population>Pharmacokinetic Population. One participant from GSK2838232 100 mg arm was dosed with GSK2838232 50 mg on Days 1 and 2; hence, pharmacokinetic parameters for that participant were summarized with GSK2838232 50 mg for Day 1</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.033" lower_limit="3.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="3.250" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="6.000" lower_limit="3.00" upper_limit="8.00"/>
                    <measurement group_id="O4" value="4.000" lower_limit="2.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absorption Lag Time (Tlag) for GSK2838232 on Day 1</title>
        <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
        <time_frame>Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 1</time_frame>
        <population>Pharmacokinetic Population. One participant from GSK2838232 100 mg arm was dosed with GSK2838232 50 mg on Days 1 and 2; hence, pharmacokinetic parameters for that participant were summarized with GSK2838232 50 mg for Day 1</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Absorption Lag Time (Tlag) for GSK2838232 on Day 1</title>
          <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
          <population>Pharmacokinetic Population. One participant from GSK2838232 100 mg arm was dosed with GSK2838232 50 mg on Days 1 and 2; hence, pharmacokinetic parameters for that participant were summarized with GSK2838232 50 mg for Day 1</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.083" lower_limit="0.50" upper_limit="1.58"/>
                    <measurement group_id="O2" value="1.000" lower_limit="0.00" upper_limit="1.53"/>
                    <measurement group_id="O3" value="0.500" lower_limit="0.00" upper_limit="1.50"/>
                    <measurement group_id="O4" value="0.500" lower_limit="0.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration of GSK2838232 at 24 Hours Post-dose on Day 1</title>
        <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
        <time_frame>24 hours post-dose on Day 1</time_frame>
        <population>Pharmacokinetic Population. One participant from GSK2838232 100 mg arm was dosed with GSK2838232 50 mg on Days 1 and 2; hence, pharmacokinetic parameters for that participant were summarized with GSK2838232 50 mg for Day 1</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of GSK2838232 at 24 Hours Post-dose on Day 1</title>
          <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
          <population>Pharmacokinetic Population. One participant from GSK2838232 100 mg arm was dosed with GSK2838232 50 mg on Days 1 and 2; hence, pharmacokinetic parameters for that participant were summarized with GSK2838232 50 mg for Day 1</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.890" spread="27.6"/>
                    <measurement group_id="O2" value="13.45" spread="87.3"/>
                    <measurement group_id="O3" value="30.72" spread="58.3"/>
                    <measurement group_id="O4" value="87.33" spread="54.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve Over the Dosing Interval (AUC [0 to Tau]) for GSK2838232 on Day 10</title>
        <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
        <time_frame>Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 10</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve Over the Dosing Interval (AUC [0 to Tau]) for GSK2838232 on Day 10</title>
          <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the specified time point were analyzed.</population>
          <units>Hours*nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="590" spread="33.4"/>
                    <measurement group_id="O2" value="1024" spread="40.8"/>
                    <measurement group_id="O3" value="2727" spread="53.1"/>
                    <measurement group_id="O4" value="5664" spread="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pre-dose Concentration (C0) of GSK2838232 on Day 10</title>
        <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
        <time_frame>Pre dose on Day 10</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose Concentration (C0) of GSK2838232 on Day 10</title>
          <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the specified time point were analyzed.</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.02" spread="28.8"/>
                    <measurement group_id="O2" value="36.66" spread="39.8"/>
                    <measurement group_id="O3" value="75.31" spread="57.0"/>
                    <measurement group_id="O4" value="155.5" spread="64.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration at End of Dosing Interval (Ctau) for GSK2838232 on Day 10</title>
        <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
        <time_frame>24 hours post-dose on Day 10</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration at End of Dosing Interval (Ctau) for GSK2838232 on Day 10</title>
          <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the specified time point were analyzed.</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.24" spread="33.7"/>
                    <measurement group_id="O2" value="31.76" spread="53.8"/>
                    <measurement group_id="O3" value="78.98" spread="58.3"/>
                    <measurement group_id="O4" value="180.3" spread="79.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for GSK2838232 on Day 10</title>
        <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
        <time_frame>Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 10</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for GSK2838232 on Day 10</title>
          <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the specified time point were analyzed.</population>
          <units>Nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.65" spread="30.8"/>
                    <measurement group_id="O2" value="56.40" spread="33.0"/>
                    <measurement group_id="O3" value="157.9" spread="54.0"/>
                    <measurement group_id="O4" value="306.5" spread="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Oral Clearance of GSK2838232 Following Administration on Day 10</title>
        <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
        <time_frame>Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 10</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance of GSK2838232 Following Administration on Day 10</title>
          <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the specified time point were analyzed.</population>
          <units>Liters per hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.91" spread="33.4"/>
                    <measurement group_id="O2" value="48.84" spread="40.8"/>
                    <measurement group_id="O3" value="36.67" spread="53.1"/>
                    <measurement group_id="O4" value="35.31" spread="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Half-life (T1/2) of GSK2838232 Following Administration on Day 10</title>
        <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
        <time_frame>Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 10</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (T1/2) of GSK2838232 Following Administration on Day 10</title>
          <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the specified time point were analyzed.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.221" spread="17.1"/>
                    <measurement group_id="O2" value="16.298" spread="24.0"/>
                    <measurement group_id="O3" value="18.113" spread="18.3"/>
                    <measurement group_id="O4" value="16.351" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax for GSK2838232 Following Administration on Day 10</title>
        <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
        <time_frame>Pre dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 10</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax for GSK2838232 Following Administration on Day 10</title>
          <description>Serial plasma samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the specified time point were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.000" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="4.000" lower_limit="2.00" upper_limit="8.05"/>
                    <measurement group_id="O3" value="6.000" lower_limit="3.00" upper_limit="8.10"/>
                    <measurement group_id="O4" value="4.083" lower_limit="2.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 11 in log10 Plasma HIV-1 RNA Relative to Day 10 AUC (0 to Tau)</title>
        <description>Plasma samples were collected for quantitative analysis of HIV-1 RNA. Change from Baseline is the value at indicated time point minus Baseline value. Statistical analysis for relationship between pharmacokinetic parameters (AUC) and pharmacodynamic measures (Change from Baseline in plasma HIV-1 RNA) was explored using a frequentist three parameter Emax non-linear model. The model parameters estimated included: maximum response (Emax), pharmacokinetic parameter value that attains 50% of the maximal effect (ED50) and residual variability (s2e). Pharmacokinetic/Pharmacodynamic Population comprised of participants who met criteria for Per-Protocol (all participants who met study criteria and are enrolled into the study with documented evidence of having received all doses and all post-baseline HIV-1 RNA measurement, with exceptions of those who have at least one major protocol deviation) and Pharmacokinetic Population analysis sets and who underwent pharmacodynamic sampling during study.</description>
        <time_frame>Baseline (Day 1), Days 10 and 11</time_frame>
        <population>Pharmacokinetic/Pharmacodynamic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 11 in log10 Plasma HIV-1 RNA Relative to Day 10 AUC (0 to Tau)</title>
          <description>Plasma samples were collected for quantitative analysis of HIV-1 RNA. Change from Baseline is the value at indicated time point minus Baseline value. Statistical analysis for relationship between pharmacokinetic parameters (AUC) and pharmacodynamic measures (Change from Baseline in plasma HIV-1 RNA) was explored using a frequentist three parameter Emax non-linear model. The model parameters estimated included: maximum response (Emax), pharmacokinetic parameter value that attains 50% of the maximal effect (ED50) and residual variability (s2e). Pharmacokinetic/Pharmacodynamic Population comprised of participants who met criteria for Per-Protocol (all participants who met study criteria and are enrolled into the study with documented evidence of having received all doses and all post-baseline HIV-1 RNA measurement, with exceptions of those who have at least one major protocol deviation) and Pharmacokinetic Population analysis sets and who underwent pharmacodynamic sampling during study.</description>
          <population>Pharmacokinetic/Pharmacodynamic Population</population>
          <units>log10 copies per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4979" spread="0.44873"/>
                    <measurement group_id="O2" value="-1.1671" spread="0.51996"/>
                    <measurement group_id="O3" value="-1.1745" spread="0.45005"/>
                    <measurement group_id="O4" value="-1.5994" spread="0.32718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Emax</param_type>
            <param_value>-1.822</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.333</ci_lower_limit>
            <ci_upper_limit>1.310</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>ED50</param_type>
            <param_value>1020.755</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>100.786</ci_lower_limit>
            <ci_upper_limit>1940.724</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>s2e</param_type>
            <param_value>0.200</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.095</ci_lower_limit>
            <ci_upper_limit>0.306</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 11 in log10 Plasma HIV-1 RNA Relative to Day 10 Cmax</title>
        <description>Plasma samples were collected for quantitative analysis of HIV-1 RNA. Change from Baseline is the value at indicated time point minus Baseline value. Statistical analysis for the relationship between pharmacokinetic parameters (Cmax) and pharmacodynamic measures (change from Baseline in log10 plasma HIV-1 RNA) was explored using a frequentist three parameter Emax non-linear model. The model parameters estimated included: maximum response (Emax), pharmacokinetic parameter value that attains the 50% of the maximal effect (ED50) and s2e.</description>
        <time_frame>Baseline (Day 1), Days 10 and 11</time_frame>
        <population>Pharmacokinetic/Pharmacodynamic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 11 in log10 Plasma HIV-1 RNA Relative to Day 10 Cmax</title>
          <description>Plasma samples were collected for quantitative analysis of HIV-1 RNA. Change from Baseline is the value at indicated time point minus Baseline value. Statistical analysis for the relationship between pharmacokinetic parameters (Cmax) and pharmacodynamic measures (change from Baseline in log10 plasma HIV-1 RNA) was explored using a frequentist three parameter Emax non-linear model. The model parameters estimated included: maximum response (Emax), pharmacokinetic parameter value that attains the 50% of the maximal effect (ED50) and s2e.</description>
          <population>Pharmacokinetic/Pharmacodynamic Population.</population>
          <units>log10 copies per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4979" spread="0.44873"/>
                    <measurement group_id="O2" value="-1.1671" spread="0.51996"/>
                    <measurement group_id="O3" value="-1.1745" spread="0.45005"/>
                    <measurement group_id="O4" value="-1.5994" spread="0.32718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Emax</param_type>
            <param_value>-1.801</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.319</ci_lower_limit>
            <ci_upper_limit>-1.283</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>ED50</param_type>
            <param_value>55.572</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.565</ci_lower_limit>
            <ci_upper_limit>107.579</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>s2e</param_type>
            <param_value>0.206</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.097</ci_lower_limit>
            <ci_upper_limit>0.314</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 11 in log10 Plasma HIV-1 RNA Relative to Day 10 Ctau</title>
        <description>Plasma samples were collected for quantitative analysis of HIV-1 RNA. Change from Baseline is the value at indicated time point minus Baseline value. Statistical analysis for the relationship between pharmacokinetic parameters (Ctau) and pharmacodynamic measures (change from Baseline in log10 plasma HIV-1 RNA) was explored using a frequentist three parameter Emax non-linear model. The model parameters estimated included: maximum response (Emax), pharmacokinetic parameter value that attains the 50% of the maximal effect (ED50) and s2e.</description>
        <time_frame>Baseline (Day 1), Days 10 and 11</time_frame>
        <population>Pharmacokinetic/Pharmacodynamic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 11 in log10 Plasma HIV-1 RNA Relative to Day 10 Ctau</title>
          <description>Plasma samples were collected for quantitative analysis of HIV-1 RNA. Change from Baseline is the value at indicated time point minus Baseline value. Statistical analysis for the relationship between pharmacokinetic parameters (Ctau) and pharmacodynamic measures (change from Baseline in log10 plasma HIV-1 RNA) was explored using a frequentist three parameter Emax non-linear model. The model parameters estimated included: maximum response (Emax), pharmacokinetic parameter value that attains the 50% of the maximal effect (ED50) and s2e.</description>
          <population>Pharmacokinetic/Pharmacodynamic Population.</population>
          <units>log10 copies per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4979" spread="0.44873"/>
                    <measurement group_id="O2" value="-1.1671" spread="0.51996"/>
                    <measurement group_id="O3" value="-1.1745" spread="0.45005"/>
                    <measurement group_id="O4" value="-1.5994" spread="0.32718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Emax</param_type>
            <param_value>-1.846</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.352</ci_lower_limit>
            <ci_upper_limit>-1.340</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>ED50</param_type>
            <param_value>32.415</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.687</ci_lower_limit>
            <ci_upper_limit>60.143</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>s2e</param_type>
            <param_value>0.200</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.094</ci_lower_limit>
            <ci_upper_limit>0.305</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Count to Day 11</title>
        <description>CD4+ cell counts were assessed by flow cytometry. Baseline value is the latest pre-dose assessment value. Change from Baseline is calculated as the post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1) and Day 11</time_frame>
        <population>ITT Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Count to Day 11</title>
          <description>CD4+ cell counts were assessed by flow cytometry. Baseline value is the latest pre-dose assessment value. Change from Baseline is calculated as the post-dose visit value minus Baseline value.</description>
          <population>ITT Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Cells per microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="95.26"/>
                    <measurement group_id="O2" value="52.0" spread="145.36"/>
                    <measurement group_id="O3" value="40.7" spread="94.47"/>
                    <measurement group_id="O4" value="11.1" spread="75.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 11 in CD4+ Count Relative to Day 10 AUC (0 to Tau)</title>
        <description>The relationship between pharmacokinetic parameters (AUC) and pharmacodynamic measures (change from Baseline CD4+ cell count) was explored using a frequentist linear model. The model parameters estimated included slope and intercept. The estimate (slope) along with 95% confidence interval is presented.</description>
        <time_frame>Baseline (Day 1), Days 10 and 11</time_frame>
        <population>Pharmacokinetic/Pharmacodynamic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Participants Receiving GSK2838232</title>
            <description>Participants who received GSK2838232 at doses of 20 mg, 50 mg, 100 mg and 200 mg were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 11 in CD4+ Count Relative to Day 10 AUC (0 to Tau)</title>
          <description>The relationship between pharmacokinetic parameters (AUC) and pharmacodynamic measures (change from Baseline CD4+ cell count) was explored using a frequentist linear model. The model parameters estimated included slope and intercept. The estimate (slope) along with 95% confidence interval is presented.</description>
          <population>Pharmacokinetic/Pharmacodynamic Population</population>
          <units>cells/microliter/ng*h/mL</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" lower_limit="-0.016" upper_limit="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 11 in CD4+ Count Relative to Day 10 Cmax</title>
        <description>The relationship between pharmacokinetic parameters (Cmax) and pharmacodynamic measures (change from Baseline CD4+ cell count) was explored using a frequentist linear model. The model parameters estimated included slope and intercept. The estimate (slope) along with 95% confidence interval is presented</description>
        <time_frame>Baseline (Day 1), Days 10 and 11</time_frame>
        <population>Pharmacokinetic/Pharmacodynamic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Participants Receiving GSK2838232</title>
            <description>Participants who received GSK2838232 at doses of 20 mg, 50 mg, 100 mg and 200 mg were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 11 in CD4+ Count Relative to Day 10 Cmax</title>
          <description>The relationship between pharmacokinetic parameters (Cmax) and pharmacodynamic measures (change from Baseline CD4+ cell count) was explored using a frequentist linear model. The model parameters estimated included slope and intercept. The estimate (slope) along with 95% confidence interval is presented</description>
          <population>Pharmacokinetic/Pharmacodynamic Population</population>
          <units>cells/microliter/nanograms/milliliter</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.067" lower_limit="-0.320" upper_limit="0.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 11 in CD4+ Count Relative to Day 10 Ctau</title>
        <description>The relationship between pharmacokinetic parameters (Ctau) and pharmacodynamic measures (change from Baseline CD4+ cell count) was explored using a frequentist linear model. The model parameters estimated included slope and intercept. The estimate (slope) along with 95% confidence interval is presented.</description>
        <time_frame>Baseline (Day 1), Days 10 and 11</time_frame>
        <population>Pharmacokinetic/Pharmacodynamic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Participants Receiving GSK2838232</title>
            <description>Participants who received GSK2838232 at doses of 20 mg, 50 mg, 100 mg and 200 mg were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 11 in CD4+ Count Relative to Day 10 Ctau</title>
          <description>The relationship between pharmacokinetic parameters (Ctau) and pharmacodynamic measures (change from Baseline CD4+ cell count) was explored using a frequentist linear model. The model parameters estimated included slope and intercept. The estimate (slope) along with 95% confidence interval is presented.</description>
          <population>Pharmacokinetic/Pharmacodynamic Population</population>
          <units>cells/microliter/nanograms/milliliter</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.079" lower_limit="-0.451" upper_limit="0.292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Emergent Drug Resistance Mutations</title>
        <description>Plasma samples were collected to evaluate treatment-emergent genotypic mutations in Gag, reverse transcriptase (RT) and protease (PR) and to assess phenotypic resistance to GSK2838232 and RT and PR drugs. Number of participants with treatment emergent RT/PR mutations, reduced susceptibility to nucleoside/nucleotide reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), or protease inhibitor (PI), treatment emergent maturation inhibitor A364A/V and GSK2838232 phenotypic resistance is presented.</description>
        <time_frame>Up to Day 11</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Emergent Drug Resistance Mutations</title>
          <description>Plasma samples were collected to evaluate treatment-emergent genotypic mutations in Gag, reverse transcriptase (RT) and protease (PR) and to assess phenotypic resistance to GSK2838232 and RT and PR drugs. Number of participants with treatment emergent RT/PR mutations, reduced susceptibility to nucleoside/nucleotide reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), or protease inhibitor (PI), treatment emergent maturation inhibitor A364A/V and GSK2838232 phenotypic resistance is presented.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RT/PR mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reduced susceptibility to NRTIs, NNRTIs, PIs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2838232 phenotypic resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment emergent A364A/V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Ratio for GSK2838232</title>
        <description>Serial blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232. The accumulation ratios were calculated as R_AUC=AUC(0-tau) Day 10/AUC(0-24) Day 1; R_Cmax=Cmax Day 10/Cmax Day 1 and R_Ctau=Ctau Day 10/C24 Day 1.</description>
        <time_frame>pre dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Days 1 and 10; pre-dose on Days 3, 4, 5, 8 and 9; Days 12 and 14</time_frame>
        <population>Pharmacokinetic Population. Only participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio for GSK2838232</title>
          <description>Serial blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232. The accumulation ratios were calculated as R_AUC=AUC(0-tau) Day 10/AUC(0-24) Day 1; R_Cmax=Cmax Day 10/Cmax Day 1 and R_Ctau=Ctau Day 10/C24 Day 1.</description>
          <population>Pharmacokinetic Population. Only participants with data available at the specified time points were analyzed.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>R_AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.149" spread="42.2"/>
                    <measurement group_id="O2" value="2.004" spread="34.4"/>
                    <measurement group_id="O3" value="3.229" spread="46.1"/>
                    <measurement group_id="O4" value="2.211" spread="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.580" spread="45.1"/>
                    <measurement group_id="O2" value="1.498" spread="40.0"/>
                    <measurement group_id="O3" value="2.753" spread="43.4"/>
                    <measurement group_id="O4" value="1.668" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_Ctau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.267" spread="41.2"/>
                    <measurement group_id="O2" value="2.118" spread="43.9"/>
                    <measurement group_id="O3" value="3.038" spread="64.8"/>
                    <measurement group_id="O4" value="2.210" spread="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Proportionality of GSK2838232</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232. Dose proportionality was assessed using a fixed effects power model. Estimated slope and 90% confidence interval is presented.</description>
        <time_frame>pre dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Days 1 and 10</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category )</population>
        <group_list>
          <group group_id="O1">
            <title>Participants Receiving GSK2838232</title>
            <description>Participants who received GSK2838232 at doses of 20 mg, 50 mg, 100 mg and 200 mg were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Proportionality of GSK2838232</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2838232. Dose proportionality was assessed using a fixed effects power model. Estimated slope and 90% confidence interval is presented.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category )</population>
          <units>slope of log dose</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-24); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.157" lower_limit="0.971" upper_limit="1.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax; Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.158" lower_limit="0.968" upper_limit="1.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C24; Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.170" lower_limit="0.968" upper_limit="1.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0 to tau); Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.012" lower_limit="0.835" upper_limit="1.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax; Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.013" lower_limit="0.845" upper_limit="1.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctau; Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.988" lower_limit="0.787" upper_limit="1.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-morning Dose Concentrations (C0) on Day 2 Through 11</title>
        <description>Blood samples were collected for pharmacokinetic analysis of GSK2838232. The pre-morning dose concentrations for Days 2 to 11 is presented. One participant from GSK2838232 100 mg arm was dosed with GSK2838232 50 mg on Days 1 and 2; hence, pharmacokinetic parameters for that participant were summarized with GSK2838232 50 mg for Days 1 and 2 and with GSK2838232 100 mg for Days 3 to 10.</description>
        <time_frame>Pre-dose on Days 2, 3, 4, 5, 8, 9, 10 and 11</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-morning Dose Concentrations (C0) on Day 2 Through 11</title>
          <description>Blood samples were collected for pharmacokinetic analysis of GSK2838232. The pre-morning dose concentrations for Days 2 to 11 is presented. One participant from GSK2838232 100 mg arm was dosed with GSK2838232 50 mg on Days 1 and 2; hence, pharmacokinetic parameters for that participant were summarized with GSK2838232 50 mg for Days 1 and 2 and with GSK2838232 100 mg for Days 3 to 10.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)</population>
          <units>Nanograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2; n=7, 9, 9, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.08" spread="1.695"/>
                    <measurement group_id="O2" value="16.39" spread="9.002"/>
                    <measurement group_id="O3" value="34.17" spread="13.990"/>
                    <measurement group_id="O4" value="96.94" spread="44.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3; n=7, 8, 10, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.99" spread="5.576"/>
                    <measurement group_id="O2" value="29.03" spread="11.870"/>
                    <measurement group_id="O3" value="51.27" spread="25.971"/>
                    <measurement group_id="O4" value="163.98" spread="91.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4; n=7, 7, 10, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.66" spread="5.771"/>
                    <measurement group_id="O2" value="31.80" spread="13.319"/>
                    <measurement group_id="O3" value="64.49" spread="26.710"/>
                    <measurement group_id="O4" value="176.28" spread="96.684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5; n=4, 6, 10, 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.03" spread="3.308"/>
                    <measurement group_id="O2" value="34.35" spread="15.626"/>
                    <measurement group_id="O3" value="76.14" spread="35.179"/>
                    <measurement group_id="O4" value="206.29" spread="69.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; n=7, 8, 10, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.72" spread="7.139"/>
                    <measurement group_id="O2" value="43.14" spread="16.664"/>
                    <measurement group_id="O3" value="86.39" spread="43.382"/>
                    <measurement group_id="O4" value="187.16" spread="110.304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9; n=7, 6, 10, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.53" spread="6.760"/>
                    <measurement group_id="O2" value="43.83" spread="18.691"/>
                    <measurement group_id="O3" value="89.32" spread="40.407"/>
                    <measurement group_id="O4" value="206.75" spread="124.166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10; n=7, 7, 10, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.76" spread="6.426"/>
                    <measurement group_id="O2" value="39.19" spread="16.502"/>
                    <measurement group_id="O3" value="84.52" spread="39.940"/>
                    <measurement group_id="O4" value="189.05" spread="107.636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11; n=7, 7, 10, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.16" spread="6.828"/>
                    <measurement group_id="O2" value="35.09" spread="16.038"/>
                    <measurement group_id="O3" value="89.87" spread="49.195"/>
                    <measurement group_id="O4" value="219.23" spread="133.552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steady State Assessment of Plasma Pre-dose Concentrations by Treatment</title>
        <description>A linear mixed model using Day, treatment and Day by treatment as fixed effects and participant as a random effect on the log-transformed pre-dose values was performed to evaluate if steady state was achieved using the Helmert transformation approach. The comparison was done as Day 8 versus the average of Days 9 and 10 values. The ratio of geometric least square mean for Day 8 versus average of Days 9 and 10 values is presented along with 95% confidence interval.</description>
        <time_frame>Pre-dose on Days 8, 9 and 10</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2838232 20 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O2">
            <title>GSK2838232 50 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O3">
            <title>GSK2838232 100 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
          <group group_id="O4">
            <title>GSK2838232 200 mg</title>
            <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Steady State Assessment of Plasma Pre-dose Concentrations by Treatment</title>
          <description>A linear mixed model using Day, treatment and Day by treatment as fixed effects and participant as a random effect on the log-transformed pre-dose values was performed to evaluate if steady state was achieved using the Helmert transformation approach. The comparison was done as Day 8 versus the average of Days 9 and 10 values. The ratio of geometric least square mean for Day 8 versus average of Days 9 and 10 values is presented along with 95% confidence interval.</description>
          <population>Pharmacokinetic Population</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.924" lower_limit="0.778" upper_limit="1.097"/>
                    <measurement group_id="O2" value="0.999" lower_limit="0.839" upper_limit="1.189"/>
                    <measurement group_id="O3" value="0.958" lower_limit="0.830" upper_limit="1.106"/>
                    <measurement group_id="O4" value="0.961" lower_limit="0.818" upper_limit="1.128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs and non-serious AEs were collected from the start of study treatment until Day 22</time_frame>
      <desc>SAEs and non-serious AEs were collected in the Safety Population</desc>
      <group_list>
        <group group_id="E1">
          <title>GSK2838232 20 mg</title>
          <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 20 milligrams (mg) and 150 mg cobicistat once daily with a light breakfast meal and 240 milliliters (mL) of water from Day 1 to Day 10.</description>
        </group>
        <group group_id="E2">
          <title>GSK2838232 50 mg</title>
          <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 50 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
        </group>
        <group group_id="E3">
          <title>GSK2838232 100 mg</title>
          <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 100 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
        </group>
        <group group_id="E4">
          <title>GSK2838232 200 mg</title>
          <description>Eligible HIV-1 infected participants were administered a single oral dose of GSK2838232 200 mg and 150 mg cobicistat once daily with a light breakfast meal and 240 mL of water from Day 1 to Day 10.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Medical device site dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Medical device site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

